38 results about "MRI contrast agent" patented technology

The invention relates to the field of medicine. In particular, the present invention relates to a protein-based biosensor comprising a substrate binding protein that binds to an MRI contrast agent by a chelating agent. More specifically, the present invention relates to a glutamic acid biosensor comprising a glutamic acid binding protein bound to an MRI contrast agent, characterized in that the glutamic acid binding protein comprises SEQ ID NO: 10, preferably SEQ ID NO: 5, and a sequence encoding a fluorescent protein.

Provided herein are MRI contrast agents that are conditionally activated by an enzyme from a reporter gene coupled to a gene of interest. In some embodiments, provided herein is a platform where a substrate (blocking access of water to a Gd(III) ion) is removed by an enzyme that can be changed to accommodate a number of gene therapy targets.

The invention provides a phospholipid coated silver / manganese dioxide coprecipitation particle MRI contrast agent and a preparation method and application thereof. The prepared contrast agent has efficient MRI contrast performance, and compared with a traditional gadolinium-based contrast agent, the biological safety is higher, and the risk of heavy metal ion leakage is avoided; the contrast agent has the advantages that the contrast agent is high in targeting ability and accurate in targeting ability, phospholipid layer modified cRGD targeting molecules can specifically recognize high-expression integrin alpha v beta 3 on the surfaces of tumor cells, enrichment of the contrast agent in tumor tissues is realized, and imaging resolution and focus positioning accuracy are improved. The nano-silver / manganese dioxide composite material has good biocompatibility and multifunctional diagnosis and treatment integrated potential, creatively combines a silver / manganese dioxide coprecipitation core and a phospholipid wrapping structure, has good magnetic resonance imaging (MRI) contrast performance and biocompatibility, and shows remarkable application potential in the medical imaging fields of tumor targeted imaging, disease diagnosis and the like. And a new direction is provided for the development of MRI contrast agents.

This application discloses a hydrophilic magnetic solid nanosphere, its preparation method, and its application. The hydrophilic magnetic solid nanosphere is characterized by having a core-shell structure; the shell is a hydrophilic polymer; the core is a magnetic nanoparticle encapsulating a polymer I; the polymer I and the hydrophilic polymer are connected by amide bonds and / or ester bonds; the magnetic nanoparticles are selected from at least one substance having the general formula shown in Formula I; Zn x Fe 3‑x O4 formula I; x ranges from 0.1 to 0.9. The hydrophilic magnetic solid nanospheres are a type of superparamagnetic nanomaterial that can be used as an MRI contrast agent for diagnosis, enabling magnetically responsive T1 and T2 switching imaging.

The present invention relates to a novel compound and an MRI contrast agent containing same. The compound according to the present invention can minimize MRI contrast agent side effects caused by the release of gadolinium ions within the body, on the basis of the outstanding kinetic stability, and can be very usefully employed as an MRI contrast agent for diagnosing liver diseases, owing to the superior level of contrast enhancement for the liver in an MRI image of the body in comparison with other organs.

This provides a macrocyclic complex for improving in vivo MR imaging. [Solution] A novel Fe(III) macrocyclic complex having a hydroxy pendant with a third anionic auxiliary is provided. This complex has the following general structure: TIFF2026136141000214.tif33169 High-spin Fe(III) is chelated into a macrocyclic core having the structure of formula (I) or formula (II).

This invention provides high sensitivity 19 A fluorine-containing molecule suitable as an F-MRI contrast agent, and a material containing the fluorine-containing molecule as an active ingredient. 19 We provide F-MRI contrast agents. [Solution] A peptide comprising two or more amino acids linked by peptide bonds, wherein the peptide contains a fluorine-containing alkyl group and an organic radical within the same amino acid residue; the peptide according to the above, wherein the fluorine-containing alkyl group is a perfluoroalkyl group having 1 to 6 carbon atoms; the peptide according to the above, wherein the fluorine-containing alkyl group is a trifluoromethyl group or a nonafluoro-tert-butyl group; the peptide according to the above, wherein the organic radical is an N-oxyl radical: A pharmaceutical composition containing any of the above peptides; and a pharmaceutical composition containing any of the above peptides as an active ingredient. 19 F-MRI contrast agent.

The invention discloses a freeze-dried and redissolved iron oxide MRI (Magnetic Resonance Imaging) contrast agent preparation and a stabilizer composition thereof. The preparation comprises superparamagnetic iron oxide nanoparticles and the stabilizer composition consisting of mannitol, trehalose, a polyethylene glycol derivative and glycine in a specific concentration ratio. According to the composition, through the synergistic effect of multiple components, the ice crystal size can be effectively controlled in the freeze-drying process, coordination aggregation of iron ions among particles is blocked, and the collapse temperature of a system is increased, so that a freeze-dried cake body with a complete structure is obtained; and the particle size and the magnetic resonance relaxation performance (r2) of the redissolved superparamagnetic iron oxide nanoparticles are highly maintained. The preparation solves the technical bottleneck that the existing superparamagnetic iron oxide contrast agent is poor in stability, depends on a cold chain and is short in shelf life, realizes long-term stable storage at room temperature and clinical rapid redissolution use, and has important clinical application value.

The invention relates to the technical field of biomedical materials, in particular to a gadolinium oxide-based nano preparation as well as a preparation method and application thereof. The preparation method of the preparation comprises the following steps: preparing gadolinium oxide nanoparticles through a hydrothermal method and amination modification, and dissolving the gadolinium oxide nanoparticles in deionized water to obtain a contrast agent solution; dropwise adding the nano-particles into a gold source solution under stirring at a certain temperature to obtain nano-particles with core-shell structures; and finally, slowly adding the synthesized dispersant solution of the water-soluble polymer into the core-shell nanoparticle solution to obtain a gadolinium oxide-based nano preparation solution. And performing post-treatment such as dialysis, freeze drying and the like to obtain the core-shell structure nanoparticles based on the gadolinium oxide nano preparation. The invention relates to a gadolinium oxide-based nano preparation for cancer diagnosis and treatment, gadolinium oxide is used as an MRI contrast agent, and a gold shell is grown on the periphery of the gadolinium oxide as a photo-thermal preparation; the hydrogel has the characteristics of good biocompatibility and the like, and has an important practical prospect in the field of preparation of diagnosis and treatment integrated medicines.

The present invention relates to an orally administrable complex having an average hydrated particle diameter of 10 nm to 100 nm and comprising: a core composed of metal or metal oxide-based nanoparticle(s); and a shell disposed as an acid-resistant barrier layer on the surface of the core and coated with polysaccharide crosslinked colloidal particles which form multi-point coordination bonds with metal ions on the surface of the core and have an average hydrated particle diameter of 2 nm to 8 nm and a surface charge of -20 mV to 0 mV. The polysaccharide crosslinked colloidal particles are characterized in that, in an aqueous solvent, (i) an -OH functional group of a monosaccharide, which is a building block of a linear polysaccharide, a branched polysaccharide, or a cyclic polysaccharide, is modified using a first crosslinking agent having an epoxide group, and (a) the functional group modified by the first crosslinking agent and a spatially adjacent -OH functional group are directly crosslinked and / or (b) two spatially adjacent functional groups modified by the first crosslinking agent are crosslinked intramolecularly and / or intermolecularly via a second crosslinking agent having two or more amine groups (-NH2) to form polysaccharide crosslinked particles, and (ii) the number of crosslinking agent-derived basic amine groups exposed on the surface is modified with a -COOH functional group so that the surface charge of the polysaccharide crosslinked colloidal particles is in the range of -20 mV to 0 mV. The orally administrable complex according to the present invention is a T2 MRI contrast agent that can be used as an active ingredient of a composition for diagnostic biliary and pancreatic imaging.

To provide macrocyclic compounds that can be complexed with Fe(III).SOLUTION: The macrocyclic complexes or macrocyclic compounds have a 1,4,7-triazacyclononane (TACN) moiety with one or more amine group(s) or an O- or S- substituted TACN moiety. The macrocyclic complexes have a high-spin Fe(III) atom coordinated to the TACN moiety. The macrocyclic complexes can be used in imaging methods.SELECTED DRAWING: None

The invention relates to the technical field of biological materials, particularly provides folic acid-DOTA dual-functional nanoparticles for early-stage MRI (magnetic resonance imaging) detection of cancers, and also provides a preparation method of the folic acid-DOTA dual-functional nanoparticles and application of the folic acid-DOTA dual-functional nanoparticles in contrast imaging. The folic acid-DOTA dual-functional nano-particle provided by the invention comprises a hollow silicon dioxide nano-particle, the folic acid-PEG-maleimide and the DOTA-Gd are loaded on the surfaces of the hollow silicon dioxide nano particles. According to the invention, folic acid-PEG-maleimide is modified on the surfaces of hollow silicon dioxide nanoparticles, and specific enrichment of the MRI contrast agent in lung cancer tissues is realized by using a folic acid receptor mediated active targeting mechanism; meanwhile, by loading DOTA-Gd on the surface, the effective imaging window time is prolonged, the release risk of free gadolinium ions is reduced, and a safe and efficient nano radiography system is provided for precise diagnosis of lung cancer.

The present invention relates to a novel compound and an MRI contrast agent containing same. The compound according to the present invention can minimize MRI contrast agent side effects caused by the release of gadolinium ions within the body, on the basis of the outstanding kinetic stability, and can be very usefully employed as an MRI contrast agent for diagnosing liver diseases, owing to the superior level of contrast enhancement for the liver in an MRI image of the body in comparison with other organs.

Disclosed is a gadolinium-based compound, and an MRI contrast agent including same. The gadolinium-based compound may be a DO3A-based gadolinium compound to which 4-hydroxybenzoic acid is bound. The MRI contrast agent may include the compound. Also disclosed is a pharmaceutical composition for preventing or treating neuroinflammatory diseases, wherein the composition comprises the compound or a pharmaceutically acceptable salt thereof.

This invention discloses a Fe-based T7 peptide-targeting small-molecule magnetic resonance imaging (MRI) contrast agent for gliomas, its synthesis method, and its applications. The small-molecule MRI contrast agent comprises a targeting peptide and an iron-coordinated pyridine ring contrast agent, linked by a click reaction. The T7 peptide portion of this small-molecule MRI contrast agent can bind to transferrin receptors, allowing for more efficient delivery to the brain for imaging. Compared to traditional Gd-based contrast agents, the MRI contrast agent of this invention exhibits higher specificity and lower toxicity, while also demonstrating better stability, enabling efficient imaging of in situ gliomas.

We report a chelator platform based on diazapyridinophane macrocycles as contrast agents to improve Magnetic Resonance Imaging. Lead compounds identified, [Mn(TE-1)]+ and [Mn(TE-4)], have good relaxivity and kinetic inertness in vivo. Spectrophotometric titrations and in vitro Zn challenge studies of [Mn(TE-4)] showed kinetic inertness with a rate of dissociation of 6.8 x 10-4 s-1, while [Mn(TE-1)]+ has a slower dissociation rate of 1.0 x 10-4 s-1 and a relaxivity of 3.6 mM -1 s-1 measured at 1.4 T magnetic field and 33 ºC. These Mn complexes were investigated by employing the 52Mn radioisotope, a positron emission tomography (PET) radiotracer, to probe kinetic inertness and stability in vivo. The Mn complexes of TE-1 and TE-4 exhibit different behavior in in vivo MRI studies given their different lipophilicity: [Mn(TE-4)] shows contrast enhancement in the kidney and bladder, indicating renal clearance, while the lipophilicity of [Mn(TE-1)]+ promotes a mixed biliary-renal excretion.

The invention belongs to the technical field of medical contrast agents, and discloses a preparation method of a superfine gadolinium oxide T1-MRI contrast agent, which comprises the following steps: S1, preparing hydrophobic gadolinium oxide nanoparticles Gd2O3-OA with stable surface oleic acid by adopting a high-temperature thermal decomposition method; s2, the Gd2O3-OA and gallic acid are subjected to a reaction, and Gd2O3-GA nano particles are obtained; and S3, carrying out a reaction on the Gd2O3-GA and citric acid under an alkaline condition to obtain the ultrafine gadolinium oxide nanoparticles Gd2O3-CA modified by the citric acid. The Gd2O3-CA nano-particles prepared by the method in the scheme are uniform in particle size and superfine in particle size, and have better water dispersibility and stability. The nanoparticles have higher longitudinal relaxation rate and better in-vivo radiography effect, and can realize rapid removal through kidney metabolism at the same time, so that the risk of gadolinium ion deposition is reduced.

The application discloses a fluorinated monosaccharide derivative and a synthesis method and application thereof. The fluorinated monosaccharide derivative is composed of three parts, the first part is a 1-substituted monosaccharide group, the second part is a fluorine signal source perfluoro-t-butyl ether group, and the third part is a triazole ring connecting the two. The fluorinated monosaccharide derivative of the application retains the 2-hydroxyl and 6-hydroxyl of the monosaccharide, thereby not affecting the recognition of the monosaccharide in the body, and having good water solubility and biocompatibility. The derivative contains nine magnetically equivalent fluorine-19, can produce a single and strong fluorine signal, and avoids problems such as fluorine signal splitting or low fluorine atom utilization. The fluorine signal strength has a good linear relationship with the concentration of the compound, which provides a basis for in vivo quantification 19 F MRI. 19 F MRI imaging of HepG2 cells has the potential to be used as a tumor selective 19 F MRI contrast agent.

The present invention improves an existing contrast agent, especially, a T1 contrast agent, and adopts a strategy in which the T1 contrast material is partially coated on a support surface to which a hydrophilic functional group is exposed. The partial coating strategy adopted in the present invention improves both the stability and contrast performance of T1 contrast agent nanoparticles, and such a strategy leads to very interesting technical development.

Disclosed is a gadolinium-based compound, and an MRI contrast agent including same. The gadolinium-based compound may be a DO3A-based gadolinium compound to which vanillic acid is bound. The MRI contrast agent may include the compound. Also disclosed is a pharmaceutical composition for preventing or treating neuroinflammatory diseases, wherein the composition comprises the compound or a pharmaceutically acceptable salt thereof.

Provided herein are MRI contrast agents that are conditionally activated by an enzyme from a reporter gene coupled to a gene of interest. In some embodiments, provided herein is a platform where a substrate (blocking access of water to a Gd(III) ion) is removed by an enzyme that can be changed to accommodate a number of gene therapy targets.

A photothermal magnetic resonance imaging enhancement agent includes composite nanoparticles. The composite nanoparticle includes an inner layer of a dielectric material with a porous substrate having pores, an inner layer with a core, magnetically responsive nanoparticles disposed on the porous substrate, and an outer layer of a metallic material around the inner layer and the magnetically responsive nanoparticles. A method of making a photothermal magnetic resonance imaging enhancement agent includes synthesizing a dielectric substrate, baking the dielectric substrate to generate pores, synthesizing magnetically responsive nanoparticles, loading the magnetically responsive nanoparticles into the pores, attaching linker molecules to the dielectric core, attaching a metal nanoparticle to at least a portion of the linker molecules, reducing additional metal onto the metal nanoparticles to form an outer layer disposed on the dielectric inner layer, and selecting reducing a condition such that the outer layer has a controllable thickness forming a composite nanoparticle.

The present invention improves an existing contrast agent, especially, a T1 contrast agent, and adopts a strategy in which the T1 contrast material is partially coated on a support surface to which a hydrophilic functional group is exposed. The partial coating strategy adopted in the present invention improves both the stability and contrast performance of T1 contrast agent nanoparticles, and such a strategy leads to very interesting technical development.

Provided are macrocyclic compounds and compounds with two or more macrocyclic groups, iron coordinated macrocyclic compounds, and iron coordinated compounds with two or more macrocyclic groups. The iron is high-spin iron(III). The iron coordinated compounds may exhibit a negative redox potential (e.g., relative to a normal hydrogen electrode at a biologically relevant pH, for example, a pH of 6.5-7.5). The compounds can be used as MRI contrast agents.

A gadolinium-based compound and an MRI contrast agent comprising same are disclosed. The gadolinium-based compound may be a DO3A-based gadolinium compound bound to protocatechuic acid. The MRI contrast agent may comprise the compound. In addition, disclosed is a pharmaceutical composition for preventing or treating neuroinflammatory diseases, comprising the compound or a pharmaceutically acceptable salt thereof.

The present invention relates to the use of a formation agent, such as nitric oxide or sodium nitrite to produce methemoglobin as an alternative MRI contrast agent. The formation agent can be infused using either a respiratory system or a delivery mechanism. One embodiment of this invention relates to systems and methods for producing an image of an internal region with a magnetic resonance scanning system. Blood is drawn from the patient. The blood is exposed to formation agent through a delivery system, to produce blood that has a higher saturation of methemoglobin. Where in vitro techniques are used the treated blood is injected back into the patient. The patient is scanned in the magnetic resonance scanner. These systems and methods can be used to produce images of regions which may not otherwise be possible with other contrasting agents. For example, an accurate vascular brain MRI may not be as informative if the patient is injected with an existing contrasting agent. In addition, an alternate embodiment of the invention relates to internally exposing the blood to the formation agent by placing the gas-permeable membrane along a particular blood pathway or intravenous sodium nitrite.

This invention discloses a magnetic resonance imaging (MRI) contrast agent for targeted detection of collagen molecular structural denaturation, its preparation method, and its application. The general chemical formula of this MRI contrast agent is: [X] m -L-(GfO) n Among them, (GfO) n [n] is a collagen hybrid peptide, where n is a positive integer between 6 and 12; L is a linker, comprising amino acids and / or amino acid derivatives; [X] is a paramagnetic metal complex, composed of a chelating agent and paramagnetic metal ions; m represents the number of paramagnetic metal complexes, where m is a positive integer between 1 and 12. The magnetic resonance contrast agent of this invention can target and detect degenerated collagen, exhibiting higher lesion specificity and detection sensitivity compared to conventional targeted contrast agents that rely on differences in collagen content for imaging. Furthermore, this magnetic resonance contrast agent can significantly enhance the magnetic resonance signal of damaged and degenerated cartilage, Achilles tendon, and abdominal aortic aneurysm, facilitating the early diagnosis of collagen degeneration-related diseases.